GO TO CORPORATE ABOUT US WHAT WE DO INVESTOR & MEDIA CAREERS COMPANY OVERVIEW Bavarian Nordic focuses on developing product candidates to address cancer and infectious diseases by leveraging several core strengths: Extensive R&D expertise in vaccines and immunotherapy Broadly applicable platform technology Multiple clinical stage development programs, including two Phase 3 trials Flexible, commercial scale manufacturing facility Significant financial resources resulting from IMVAMUNE® supply contracts and government-funded R&D programs Through a long-standing collaboration with the U.S. Government, Bavarian Nordic has developed a portfolio of biological countermeasures, including the non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use by the U.S. and other governments. The vaccine is approved in the EU (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its partner Janssen are pioneering the development of an Ebola vaccine, which has been fast-tracked by authorities in response to the current situation in West Africa. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies based on its versatile pox-virus based technologies, including PROSTVAC®, which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC. Bavarian Nordic's shares are listed on Nasdaq Copenhagen under the symbol BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol BVNRY. OUR LOCATIONS OUR LOCATIONS FACTS Listed on Nasdaq Copenhagen 420+ employees in Denmark, Germany and the USA Ongoing contracts with the U.S. Government worth more than US$ 1 billion Download fact sheet here CONTACT US +45 33 26 83 83 info@bavarian-nordic.com FOLLOW US ABOUT US Bavarian Nordic is a biopharmaceutical company focused on the development and manufacturing of cancer immunotherapies and vaccines for infectious diseases. OUR LOCATIONS © 2015 Bavarian Nordic | Disclaimer/Privacy | Cookies | Sitemap This website uses cookies to collect statistical information on the use of our website with the goal of improving user experience. To find out more about cookies on this website, see our cookie policy.

GO TO CORPORATE ABOUT US WHAT WE DO INVESTOR & MEDIA CAREERS EXECUTIVE MANAGEMENT Paul Chaplin President & CEO View more Ole Larsen Executive Vice President, Chief Financial Officer View more CONTACT US +45 33 26 83 83 info@bavarian-nordic.com FOLLOW US ABOUT US Bavarian Nordic is a biopharmaceutical company focused on the development and manufacturing of cancer immunotherapies and vaccines for infectious diseases. OUR LOCATIONS © 2015 Bavarian Nordic | Disclaimer/Privacy | Cookies | Sitemap This website uses cookies to collect statistical information on the use of our website with the goal of improving user experience. To find out more about cookies on this website, see our cookie policy.